http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Tian Yang ),( Ming-da Wang ),( Chao Li ),( Lei Liang ),( Hao Xing ),( Li-yang Sun ),( Bing Quan ),( Han Wu ),( Xin-fei Xu ),( Timothy M ),( Pawlik ),( Wan Yee Lau ),( Feng Shen ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Survival after liver resection of hepatocellular carcinoma (HCC) remains poor due to a high incidence of recurrence. We sought to investigate risk factors, patterns, and long-term prognosis among patients with early and late recurrence after liver resection for hepatitis B virus (HBV)-associated HCC. Methods: Data of consecutive patients undergoing curative resection for HBV-associated HCC were analyzed. According to the time to recurrence after surgery, recurrence was divided into early (≤ 2 years) and late recurrence (> 2 years). Characteristics, patterns of initial recurrence and post-recurrence survival (PRS) were compared between patients with early and late recurrence. Risk factors of early and late recurrence, and predictors of PRS were identified by univariable and multivariable Cox-regression analyses. Results: mong 894 patients, 322 (36.0%) and 282 (31.5%) developed early and late recurrence, respectively. On multivariable analyses preoperative HBV-DNA>104 copies/ml was associated with both early and late recurrence, while postoperative no/ irregular antiviral therapy was associated with late recurrence. Compared with patients with late recurrence, patients with early recurrence had a lower proportion of intrahepatic only recurrence (72.0% vs. 91.1%, P<0.001), as well as a lower chance of receiving potentially-curative treatments for recurrence (33.9% vs. 50.7%, P<0.001) and a worse median PRS (19.1 vs. 37.5 months, P<0.001). Multivariable analysis demonstrated that early recurrence was independently associated with worse PRS (HR 1.361, 95%CI 1.094-1.692, P=0.006). Conclusions: Although risk factors associated with early recurrence and late recurrence were different, a high preoperative HBV-DNA load was an independent hepatitis-related risk for both early and late recurrence. Early recurrence was associated with
( Tian Yang ),( Hai-su Dai ),( Lei Liang ),( Cheng-cheng Zhang ),( Zhang-jun Cheng ),( Yong-hai Peng ),( Yao-ming Zhang ),( Zhi-yu Chen ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Iatrogenic biliary injury (IBI) following laparoscopic cholecystectomy (LC) is the most common and recognized iatrogenic complications. Little is known whether LC-IBI would lead to surgeon’s mental distress. This study reports the incidence of surgeon’s mental distress who have caused LC-IBI and risk factors of surgeon’s severe mental distress (SMD). Methods: A cross-sectional survey in the form of electronic questionnaire was conducted among Chinese general surgeons who have caused LC-IBI. The six collected clinical features relating to mental distress included: 1) feeling burnout, anxiety, or depression, 2) avoiding performing LC, 3) having physical reactions when recalling the incidence, 4) having the urge to quit surgery, 5) taking psychiatric medications, and 6) seeking professional psychological counseling. Univariable and multivariable analyses were performed to identify risk factors of SMD, which was defined as meeting ≥3 of the above-mentioned clinical features. Results: Among 1,466 surveyed surgeons, 1,236(84.3%) experienced mental distress following LC-IBI, and nearly half (49.7%, 614/1236) had SMD. Multivariable analyses demonstrated that surgeons from non-university affiliated hospitals (OR:1.873), patients who required multiple repair operations (OR:4.075), patients who required hepaticojejunostomy/partial hepatectomy (OR:1.859), existing lawsuit litigation (OR:10.491), existing violent doctor-patient conflicts (OR:4.995), needing surgeons’ personal compensation (OR:2.531), and additional administrative punishment by hospitals (OR:2.324) were independent risk factors of surgeon’s SMD. Conclusions: Four out of five surgeons experienced mental distress following LC-IBI, and nearly half had SMD. Several independent risk factors of SMD were identified, which could help to make strategies to improve mental well-being of these surgeons.
Yang, Jian,Li, Chuan,Wen, Tian-Fu,Yan, Lu-Nan,Li, Bo,Wang, Wen-Tao,Yang, Jia-Yin,Xu, Ming-Qing Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.17
Background: This retrospective study aimed to validate the safety and effectiveness of hepatectomy for huge hepatocellular carcinoma (HCC). Materials and Methods: Data of patients who underwent hepatectomy for HCC between January 2006 and December 2012 were reviewed. The patients were divided into three groups: huge HCC(${\geq}10cm$ in diameter), large HCC(${\geq}5$ but<10 cm in diameter) and small HCC(<5cm in diameter). Results: Characteristics of pre-operative patients in all three groups were homogeneously distributed except for alpha fetal protein (AFP)(p<0.001).The 30, 60, 90-day post-operative mortality rates were not different among the three groups (p=0.785, p=0.560, and p=0.549). Laboratory data at 1, 3, and 7 days after surgery also did not vary. The 5-year overall survival (OS) and 5-year disease-free survival (DFS) rates in the huge and large HCC groups were lower than that of the small HCC group (OS: 32.5% vs 36.3% vs 71.2%, p=0.000; DFS: 20.0% vs 24.8% vs 40.7%, p=0.039), but there was no difference between the huge and large HCC groups (OS: 32.5% vs 36.3%, p=0.667; DFS: 20.0% vs 24.8%, p=0.540). In multivariate analysis, five independent poor prognostic factors that affected OS were significantly associated with worse survival (p<0.05), namely, AFP level, macrovascular invasion, Edmondsone Steiner grade, surgical margin and Ishak score. AFP level, macrovascular invasion, microvascular invasion, and surgical margin influenced disease-free survival independently (p<0.05). Conclusions: The safety of hepatectomy for huge HCC is similar to that for large and small HCC; and this approach for huge HCC may achieve similar long-term survival and disease-free survival as for large HCC.
Dysregulated Fatty Acid Metabolism in Hepatocellular Carcinoma
( Ming-da Wang ),( Jun Han ),( Hao Xing ),( Han Zhang ),( Zheng Wang ),( Zhen-li Li ),( Liang Lei ),( Chao Li ),( Feng Shen ),( Tian Yang ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Studies are urgently needed on it molecular pathogenesis and biological characteristics of hepatocellular carcinoma (HCC). Dysregulation of fatty acid (FA) metabolism, in which aberrant activation of oncogenic signaling pathways alters the expression and activity of lipid-metabolizing enzymes, is an emerging hallmark of cancer cells, and it may be involved in HCC development and progression. Methods: We summarize the characteristics of FA metabolism in HCC, focusing on the pathways of FA synthesis, oxidation, uptake and transport. We also provide a brief review of the relationship between NAFLD and HCC development. Results: The current review summarizes the dysregulated FA metabolism in HCC and pathways through which this dysregulation may regulate HCC survival and growth. Aberrant activation of oncogenic signaling pathways regulates the expression and activity of lipid-metabolizing enzymes, thus reprogramming FA metabolism to promote HCC development and progression. Intracellular FAs are required for biosynthesis of most biological membrane lipids and signaling molecules, and are also used to provide energy to support HCCs survival and proliferation, when necessary, through β-oxidation process. HCC cells can employ appropriate metabolic pathways as different situation demands. Intrahepatic cholangiocarcinoma (ICC) and HCC exhibits differential requirement for de novo lipogenesis and distinct response to therapeutic approaches focusing on inhibition of exogenous FA uptake. Non-alcoholic fatty liver disease related obesity and diabetes have increasingly emerged as two major factors responsible for the rise in prevalent of HCC. Conclusions: Our understanding of dysregulated FA metabolism and associated signaling pathways may contribute to the development of novel and efficient anti-tumor approaches for patients with HCC.
Epigenetic Regulation of miR-129-2 Leads to Overexpression of PDGFRa and FoxP1 in Glioma Cells
Tian, Xiang-Yang,Zhang, Ling,Sun, Lai-Guang,Li, Ming Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.14
miR-129-2 is frequently downregulated in multiple cancers. However, how it is silenced in cancers remains unclear. Here we investigated the expression profile and potential biological function of miR-129-2 in glioblastoma (GBM), the most common and lethal form of brain tumors in adults. We showed that miR-129-2 is lost in GBM patient specimens and cultured cell lines. miR-129-2 expression could be restored upon treatment with a histone deadetylase inhibitor (trichostatin A) but not a DNA methylation inhibitor (5-Aza-2'-deoxycytidine), and more profound effect was observed with the treatment of these two drugs in combination. Furthermore, forced expression of miR-129-2 repressed the expression of major oncogenic genes such as PDGFRa and Foxp1 in GBMs. Consistently, expression of miR-129-2 significantly inhibits GBM cell proliferation in vitro. These results reveal that miR-129-2 is epigenetically regulated and functions as a tumor suppressor gene in GBMs, suggesting it may serve as a potential therapeutic target for GBM treatment.
Ming, Hai,Ming, Jun,Oh, Seung-Min,Tian, Shu,Zhou, Qun,Huang, Hui,Sun, Yang-Kook,Zheng, Junwei American Chemical Society 2014 ACS APPLIED MATERIALS & INTERFACES Vol.6 No.17
<P>A simple surfactant-assisted reflux method was used in this study for the synthesis of cocklebur-shaped Fe<SUB>2</SUB>O<SUB>3</SUB> nanoparticles (NPs). With this strategy, a series of nanostructured Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a size distribution ranging from 20 to 120 nm and a tunable surface area were readily controlled by varying reflux temperature and the type of surfactant. Surfactants such as cetyltrimethylammonium bromide (CTAB), polyvinylpyrrolidone (PVP), poly(ethylene glycol)-<I>block</I>-poly(propylene glycol)-<I>block</I>-poly(ethylene glycol) (F127) and sodium dodecyl benzenesulfonate (SDBS) were used to achieve large-scale synthesis of uniform Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a relatively low cost. A new composite of Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB> was prepared by coating the primary Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a layer of F-doped carbon (CF<SUB><I>x</I></SUB>) with a one-step carbonization process. The Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB> composite was utilized as the anode in a lithium ion battery and exhibited a high reversible capacity of 900 mAh g<SUP>–1</SUP> at a current density of 100 mA g<SUP>–1</SUP> over 100 cycles with 95% capacity retention. In addition, a new Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB>/LiNi<SUB>0.5</SUB>Mn<SUB>1.5</SUB>O<SUB>4</SUB> battery with a high energy density of 371 Wh kg<SUP>–1</SUP> (vs cathode) was successfully assembled, and more than 300 cycles were easily completed with 66.8% capacity retention at 100 mA g<SUP>–1</SUP>. Even cycled at the high temperature of 45 °C, this full cell also exhibited a relatively high capacity of 91.6 mAh g<SUP>–1</SUP> (vs cathode) at 100 mA g<SUP>–1</SUP> and retained 54.6% of its reversible capacity over 50 cycles. Introducing CF<SUB><I>x</I></SUB> chemicals to modify metal oxide anodes and/or any other cathode is of great interest for advanced energy storage and conversion devices.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/aamick/2014/aamick.2014.6.issue-17/am504144d/production/images/medium/am-2014-04144d_0009.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/am504144d'>ACS Electronic Supporting Info</A></P>
Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): a systematic review
Ming Yang,Ya-xi Shang,Zi-yu Tian,Min Xiong,Chun-li Lu,Jiang Yue,Zhang Yao,Zhang Ying-ying,Jin Xin-yan,Jin Qiu-bai,Zhang Ying-ying,Willcox Merlin L.,Liu Jian-ping 한국한의학연구원 2020 Integrative Medicine Research Vol.9 No.3
Background: The World Health Organization characterized the Coronavirus disease 2019 (COVID-19) as a pandemic on March 11th. Many clinical trials on COVID-19 have been registered, and we aim to review the study characteristics and provide guidance for future trials to avoid duplicated effort. Methods: Studies on COVID-19 registered before March 3rd, 2020 on eight registry platforms worldwide were searched and the data of design, participants, interventions, and outcomes were extracted and analyzed. Results: Three hundred and ninety-three studies were identified and 380 (96.7%) were from mainland China, while 3 in Japan, 3 in France, 2 in the US, and 3 were international collaborative studies. Two hundred and sixty-six (67.7%) aimed at therapeutic effect, others were for prevention, diagnosis, prognosis, etc. Two hundred and two studies (51.4%) were randomized controlled trials. Two third of therapeutic studies tested Western medicines including antiviral drugs (17.7%), stem cell and cord blood therapy (10.2%), chloroquine and derivatives (8.3%), 16 (6.0%) on Chinese medicines, and 73 (27.4%) on integrated therapy of Western and Chinese medicines. Thirty-one studies among 266 therapeutic studies (11.7%) used mortality as primary outcome, while the most designed secondary outcomes were symptoms and signs (47.0%). Half of the studies (45.5%) had not started recruiting till March 3rd. Conclusion: Inappropriate outcome setting, delayed recruitment and insufficient numbers of new cases in China implied many studies may fail to complete. Strategies and protocols of the studies with robust and rapid data sharing are warranted for emergency public health events, helping the timely evidence-based decision-making.